MIT Develops Durable Injectable Gels - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

MIT Develops Durable Injectable Gels



Shear-thinning hydrogels can be injected into the body to carry drugs or cells to regenerate damaged tissue, but these hydrogels are vulnerable to degradation by mechanical stresses. Chemical engineers at the Massachusetts Institute of Technology (MIT) developed a gel that is made durable by a polymeric reinforcing network, which is activated when the gel is heated to body temperature (37 °C).

The research team, led by Bradley Olsen, an assistant professor of chemical engineering at MIT, worked with a protein hydrogel that consisted of loosely packed proteins held together by links between protein segments. Polymers attached to the ends of each protein are soluble in water and float freely in the gel at lower temperatures. When heated to body temperature, however, the polymers become insoluble, separate out of solution, and join together to form a reinforcing grid within the gel.

The researchers found that gels with this reinforcing network were significantly stiffer and much slower to degrade when exposed to mechanical stress. This offers a promising way to thwart the tendency of shear thinning materials to erode once in the body, said Jason Burdick, an associate professor of bioengineering at the University of Pennsylvania, in the MIT press release.

The gels can also be tuned to degrade over time, which would be useful for long-term drug release. The researchers are now working on ways to control this feature, as well as incorporating different types of biological functions into the gels, according to the release.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search

Click here